Apricus Biosciences, Inc (NASDAQ:APRI) announced its earnings results on Thursday. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.15), Bloomberg Earnings reports. During the same quarter last year, the business earned ($0.19) earnings per share.

Apricus Biosciences (NASDAQ:APRI) traded down $0.13 during trading hours on Friday, hitting $1.57. The company had a trading volume of 376,912 shares, compared to its average volume of 207,321.

A number of equities analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $4.50 price target on shares of Apricus Biosciences in a report on Friday. Zacks Investment Research raised Apricus Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a report on Tuesday.

TRADEMARK VIOLATION WARNING: “Apricus Biosciences, Inc (APRI) Posts Earnings Results” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/03/apricus-biosciences-inc-apri-posts-earnings-results.html.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Earnings History for Apricus Biosciences (NASDAQ:APRI)

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.